Minirin Drug Interactions

It is unlikely that desmopressin will interact with drugs affecting hepatic metabolism, since desmopressin has been shown not to undergo significant liver metabolism in in vitro studies with human microsomes. However, formal in vivo interaction studies have not been performed.
Tablet, Oral lyophilisate & Nasal spray: Substances, which are known to induce SIADH, e.g. tricyclic antidepressants, selective serotonin reuptake inhibitors, chlorpromazine and carbamazepine, as well as some antidiabetics of the sulfonylurea group particularly Chlorpropamide, may cause an additive antidiuretic effect leading to an increased risk of water retention/hyponatremia (see Precautions).
Indomethacin increases the urine concentrating effect of desmopressin without influencing the duration. The effect is probably without any clinical significance.
NSAIDs may induce water retention/hyponatraemia (see Precautions).
Injection: Special attention should be given when desmopressin is co-administered with other drugs affecting water and/or sodium homeostasis, e.g. opioids, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), nonsteroidal anti-inflammatory drugs (NSAIDs), chlorpromazine, carbamazepine and some antidiabetics of the sulfonylurea group since concurrent use can lead to an increased risk of fluid retention/hyponatraemia (see Precautions).
Tablet & Oral lyophilisate: Concomitant treatment with loperamide may result in a 3-fold increase of desmopressin plasma concentrations, which may lead to an increased risk of water retention/hyponatraemia. Although not investigated, other drugs slowing intestinal transport might have the same effect.
Tablet: The concomitant use of food decreases the rate and extent of absorption of MINIRIN tablets by 40%. No significant effect was observed with respect to pharmacodynamics (urine production or osmolality).
Food intake may reduce the intensity and duration of the antidiuretic effect at low oral doses of MINIRIN tablets.